Ruiz SE, Falcón RE, Gómez ME, Ibarra GI, Sánchez VE, Luis Solís AL, Kofman S, Arana TRM

Language: Spanish
References: 14
Page: 198-202
PDF size: 91.85 Kb.

ABSTRACT

The genetic hallmark of chronic myelogenous leukemia (CML) is the t(9;22)(q34;q11), this gene fusion leads to the expression of chimeric BCR/ABL messenger RNA (mRNA), this marker is an attractive target for monitoring minimal residual disease (MDR) after bone marrow transplantation (BMT). The RT-PCR assays has become widely used for monitoring MDR after BMT for CML. We reported the cytogenetic and molecular findings in follow-up samples from 15 CML patients undergoing BMT. All 15 patients investigated before BMT by cytogenetic and RT-PCR were positive for Ph1 chromosome and BCR/ABL transcripts. Ten patients in complete remission presented for ›12 month BCR/ABL transcript negative and karyotype normal. In five patients the RT-PCR nested for BCR/ABL were positive, three developed disease recurrence, one died by relapse, the other case with BCR/ABL+ for ›12 months received donor lymphocyte infusion (DLI), then he has complete remission. We concluded that cytogenetic analysis is limited and insufficient in the monitoring of BMT and the RT-PCR provide reliable information on residual tumor burden in CML patients with BMT. The prognostic significance of a qualitative BCR/ABL can be refined by quantitative assays and this may target patients who would benefit from early intervention therapeutic.

REFERENCES

1. Faderl S, Talpaz M, Estrov Z, O´Brien S, Kurzrock R, Kantarjian H. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.

2. Melo J. The diversity of BCR/ABL fusion protein and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.

3. Arana RM, Ruiz E, Ignacio G, Baez E, Gomez E, Castro M et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukemia (CML). Clin Lab Haem 2002; 24: 145-150.

4. Hochhaus A, Weisser A, LaRosee P, Emig M et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.

5. Hochhaus A, Lin F, Reiter A, Skladny H, Hehlman R, Goldman J, Cross N. Monitoring the efficiency of interferon therapy in chronic myelogenous leukemia patients by competitive polymerase chain reaction. Leukemia 1997; 11: 541-544.

6. Hochhaus A. Detection and quantification of leukemia specific rearrangements. In: Boultwood J, Fidler C (eds). Molecular analysis of cancer. New Jersey: Humana Press, 2002; 67-96.

7. Kidd V, Lion T. Debate round table: appropiate controls for RT-PCR. Leukemia 1997 11:871-881.

8. Bagg A. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J Molecular Diag 2002; 4: 1-10.

9. Cross N, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR/ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.

10. Wang L, Bagg A, Pear W, Nowell P, Hess L. Chronic myelogenous leukemia: Laboratory diagnosis and monitoring. Genes Chromosomes & Cancer 2001, 32: 97-111.

11. Junis JJ, Sawyer JR, Ball DW. The characterization of high resolution G banded chromosomes of man. Chromosoma 1978; 67:293-307.

12. Czepulkowski BH, Bhatt B, Rooney DE. Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukaemic blood. In: Rooney DE, Czepulkowski BH (eds). Human cytogenetics. Oxford: IRL Press, 1992; 1-26.

13. Chomczynski P, Sachi N. Single step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Analytical Biochemistry 1987; 162: 156-159.

14. Cross N. Detection of BCR/ABL in hematological malignancies by RT-PCR. In: Cotter F (ed). Molecular diagnosis in cancer. New Jersey: Humana Press, 1996; 24-